CUDC-907 – 25 mg

Brand:
Cayman
CAS:
1339928-25-4
Storage:
-20
UN-No:
Non-Hazardous - /

CUDC-907 is a dual inhibitor of HDACs and phosphatidylinositol 3-kinases (PI3Ks).{47027} It inhibits HDAC activity in HeLa nuclear extracts (IC50 = 50s = 50s = 2/M phase and apoptosis and decreases cellular migration and invasion in FTC-133, THJ-29T, XTC-1, and 8505C thyroid cancer cell lines in a concentration-dependent manner.{47026} CUDC-907 (75 mg/kg) reduces tumor growth, the number of liver metastases, and HDAC2 expression in tumor tissue in the FTC-133 mouse xenograft model.  

 

Available on backorder

SKU: 25651 - 25 mg Category:

Description

A dual inhibitor of HDACs and PI3Ks; inhibits HDAC activity in HeLa nuclear extracts (IC50 = 50s = 50s = 2/M phase and apoptosis and decreases cellular migration and invasion in FTC-133, THJ-29T, XTC-1, and 8505C thyroid cancer cell lines; reduces tumor growth, the number of liver metastases, and HDAC2 expression in tumor tissue in the FTC-133 mouse xenograft model


Formal name: N-hydroxy-2-[[[2-(6-methoxy-3-pyridinyl)-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-6-yl]methyl]methylamino]-5-pyrimidinecarboxamide

Synonyms: 

Molecular weight: 508.6

CAS: 1339928-25-4

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Kinase Inhibitors|PI3K||Product Type|Biochemicals|Small Molecule Inhibitors|Deacetylases||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle|G2/M||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling